Milwaukee-based Dohmen Life Science Services, a provider of outsourced business services for biopharma and medtech innovators, has acquired Siren Interactive Corp., a Chicago-based rare disease relationship marketing company.
The acquisition will further expand Dohmen’s market-leading direct-to-patient service model by helping life science companies in the rare disease space locate, educate and interact with the patients they serve.
Siren Interactive is now a subsidiary of Dohmen Life Science Services.
“Health care is shifting from a one size fits all model driven by volume, to a more precise and bespoke care model driven by value. We created and launched DLSS as a platform for life science innovators to reach smaller, more targeted patient populations in the most direct and interactive way possible. We did it because 30 million patients in the U.S. are afflicted with 7,000 rare diseases, yet given the historically high cost of developing and commercializing blockbuster therapies, only a few hundred of these diseases have any available treatment,” said Cynthia LaConte, chief executive officer of Dohmen Life Science Services. “We believe that people living with a rare disease deserve a more efficient and effective service model; one that accelerates access to care and empowers the healthiest, most productive life possible”
Siren founder and CEO Wendy White will join Dohmen as senior vice president of their Rare Disease segment. White created her company as a result of her own personal struggle with a family member’s rare disease experience.
“Dohmen shares our commitment to improving the quality of life for people with rare disease,” said White. “Our communications and marketing capability combined with Dohmen’s expertise in finance, technology, supply chain, medical and regulatory affairs and patient support services, has the power to really revolutionize the way products and services are developed and delivered to this unique community. The Siren team is excited about joining a company with such a rich tradition of innovation and helping to create a brand new patient care model.”
